

BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/B5E4016A00DFEN.html>

Date: February 2021

Pages: 58

Price: US\$ 125.00 (Single User License)

ID: B5E4016A00DFEN

Abstracts

BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company. It develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product category consists of multiple clinical and preclinical offerings which include Naglazyme-Mucopolysaccharidosis Type VI (MPS VI), Aldurazyme-MPS I and others. The company operates through its manufacturing facilities in Novato, California. It conducts its business operations in the US, Europe, Latin America, the Middle East and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc Key Recent Developments

Feb 18,2021: BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors

Nov 05,2020: BioMarin announces third quarter 2020 total revenues of \$477 million

Oct 05,2020: Scientific Luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., joins BioMarin as Head of Research and Early Development

Sep 25,2020: Pomerantz law firm announces the filing of a class action against BioMarin Pharmaceuticals and certain officers - BMRN

Aug 04,2020: BioMarin announces second quarter 2020 total revenue growth of 11% to \$430 million

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

Table of Contents

List of Tables

List of Figures

SECTION 1 - ABOUT THE COMPANY

BioMarin Pharmaceutical Inc - Key Facts

BioMarin Pharmaceutical Inc - Key Employees

BioMarin Pharmaceutical Inc - Key Employee Biographies

BioMarin Pharmaceutical Inc - Major Products and Services

BioMarin Pharmaceutical Inc - History

BioMarin Pharmaceutical Inc - Company Statement

BioMarin Pharmaceutical Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview

BioMarin Pharmaceutical Inc - Business Description

Product Category: Aldurazyme

Overview

Performance

Product Category: Brineura

Overview

Performance

Product Category: Firdapse

Overview

Performance

Product Category: Kuvan

Overview

Performance

Product Category: Naglazyme

Overview

Performance

Product Category: Palynziq

Overview

Performance

Product Category: Vimizim

Overview

Performance

Geographical Segment: Europe

Performance

Geographical Segment: Latin America

Performance

Geographical Segment: Rest of the World

Performance

Geographical Segment: United States

Performance

BioMarin Pharmaceutical Inc - Corporate Strategy

BioMarin Pharmaceutical Inc - SWOT Analysis

SWOT Analysis - Overview

BioMarin Pharmaceutical Inc - Strengths

BioMarin Pharmaceutical Inc - Weaknesses

BioMarin Pharmaceutical Inc - Opportunities

BioMarin Pharmaceutical Inc - Threats

BioMarin Pharmaceutical Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

BioMarin Pharmaceutical Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 18, 2021: BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors

Nov 05, 2020: BioMarin announces third quarter 2020 total revenues of \$477 million

Oct 05, 2020: Scientific Luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., joins BioMarin as Head of Research and Early Development

Sep 25, 2020: Pomerantz law firm announces the filing of a class action against BioMarin Pharmaceuticals and certain officers - BMRN

Aug 04, 2020: BioMarin announces second quarter 2020 total revenue growth of 11% to \$430 million

Jul 02, 2020: BioMarin Pharmaceutical: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers

Jun 29, 2020: BioMarin Promotes Company Veteran, Brian R. Mueller, to executive vice president, CFO

May 11, 2020: BioMarin announces proposed private offering of \$500 Million of senior subordinated convertible notes

May 03, 2020: BioMarin extends Gene Therapy leadership with DiNAQOR in a preclinical collaboration and license agreement to develop Gene Therapies for Rare Genetic Cardiomyopathies

Apr 29, 2020: BioMarin announces first quarter 2020 total revenue growth of 25% to \$502 million

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

BioMarin Pharmaceutical Inc, Key Facts
BioMarin Pharmaceutical Inc, Key Employees
BioMarin Pharmaceutical Inc, Key Employee Biographies
BioMarin Pharmaceutical Inc, Major Products and Services
BioMarin Pharmaceutical Inc, History
BioMarin Pharmaceutical Inc, Subsidiaries
BioMarin Pharmaceutical Inc, Joint Venture
BioMarin Pharmaceutical Inc, Key Competitors
BioMarin Pharmaceutical Inc, Ratios based on current share price
BioMarin Pharmaceutical Inc, Annual Ratios
BioMarin Pharmaceutical Inc, Annual Ratios (Cont...1)
BioMarin Pharmaceutical Inc, Interim Ratios
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
BioMarin Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

BioMarin Pharmaceutical Inc, Performance Chart (2015 - 2019)

BioMarin Pharmaceutical Inc, Ratio Charts

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

COMPANIES MENTIONED

Tesaro Inc

Shire Pharmaceuticals International UC

Protalix BioTherapeutics Inc

Genzyme Corp

Enzon Pharmaceuticals Inc

BioSpecifics Technologies Corp

Biogen Inc

Amicus Therapeutics Inc

I would like to order

Product name: BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/B5E4016A00DFEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B5E4016A00DFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970